Two developments Thursday–Eli Lilly's strong quarterly performance and Novo Nordisk's unsolicited $9 billion bid for a startup–show why drugmakers can't get enough of weight loss

Group 1 - The core viewpoint of the article highlights the growing significance of the $72 billion anti-obesity market in the pharmaceutical industry, as evidenced by Lilly's quarterly results and Novo Nordisk's unsolicited offer for a startup [1] Group 2 - Lilly's quarterly results indicate strong performance, contributing to the overall attractiveness of the anti-obesity market [1] - Novo Nordisk's unsolicited offer for a startup underscores the competitive landscape and investment interest in the anti-obesity sector [1]